The Evolution of TKIs in ROS1+ NSCLC

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss treatment trends and emerging data in ROS1-positive non–small cell lung cancer.

EP. 1: The Prevalence of ROS1 Fusions in Advanced NSCLC

May 30th 2025

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss the prevalence of ROS1 fusions in non–small cell lung cancer.

EP. 2: Treatment Sequencing Decisions in ROS1+ NSCLC

May 30th 2025

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss treatment sequencing in ROS1-positive non–small cell lung cancer.

EP. 3: Selecting a TKI in ROS1+ NSCLC Management

May 30th 2025

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss TKI selection in ROS1-positive non–small cell lung cancer.

EP. 4: Addressing CNS Involvement in ROS1+ NSCLC

May 30th 2025

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss CNS involvement in ROS1-positive non–small cell lung cancer.

EP. 5: Pooled Data for Taletrectinib in ROS1+ NSCLC

May 30th 2025

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss data for taletrectinib in ROS1-positive non–small cell lung cancer.

EP. 6: Another FDA-Approved Option? The Potential Role for Taletrectinib in ROS1+ NSCLC

May 30th 2025

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, on how FDA approval of taletrectinib would affect ROS1-positive non–small cell lung cancer management.

EP. 7: Novel Treatment Approaches Under Investigation in ROS1+ NSCLC

May 30th 2025

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, on novel approaches being investigated in ROS1-positive non–small cell lung cancer.

x